Nitazoxanide (thiazolid, anti-protozoan drug) Licensed drug effective in the treatment of gastrointestinal infections and proposed as a broad-spectrum antiviral agent. Inhibits translation by activation eIF2α. This evidence concerns the gene EIF2A and digestive system infectious disorder.